Antioxidant enzyme Prdx1 inhibits osteoclastogenesis via suppressing ROS and NFATc1 signaling pathways

Chao Wang,Gang Wang,Fangming Song,Jinmin Zhao,Qian Liu,Jiake Xu
DOI: https://doi.org/10.1002/jcp.31431
2024-09-13
Journal of Cellular Physiology
Abstract:Fig. A proposed scheme for the inhibition effect of Prdx1 on osteoclastogenesis. RANKL‐mediated TRAF6 recruitment results in ROS production, Nrf2 activation and Keap1 degradation, as well as NFATc1 activation and downstream osteoclast specific genes. Our results indicated that Prdx1 could suppress osteoclast formation via attenuating ROS and NFATc1 singalling pathways. Bone is a dynamic organ which continuously undergoes remodeling throughout one's lifetime. Cellular production of reactive oxygen species (ROS) is essential for regulating bone homeostasis. Osteoclasts, multinucleated giant cells differentiated from macrophage lineage, are responsible for osteolytic bone conditions which are closely linked to ROS signaling pathways. In this study, an anti‐ROS enzyme, peroxiredoxin 1 (Prdx1) was found to be expressed both in bone marrow macrophages and osteoclasts. Recombinant Prdx1 protein was found to dose‐dependently inhibit ROS production and osteoclast differentiation. Mechanistically, Prdx1 protein also attenuated NFATc1 activation as well as the expression of C‐Fos, V‐ATPase‐d2, Cathepsin K, and Integrin αV. Collectively, Prdx1 is a negative regulator on osteoclast formation via inhibiting RANKL‐mediated ROS activity, thus suggesting its potential application for treating osteoclast related disorders.
cell biology,physiology
What problem does this paper attempt to address?